Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check3 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedMinor website revision updates were made: Revision v3.4.2 was added and Revision v3.4.1 was removed. No user-facing content or study data were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedAdded Revision: v3.4.1 and removed the previous notices (Revision: v3.4.0) related to government funding and operating status.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded a government funding lapse notice at the top with links to cc.nih.gov and opm.gov, and added a 2025 Arthritis Research & Therapy article citation by Gossec et al. on risankizumab in PsA while removing the online-ahead-of-print note for that citation.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a glossary display toggle; updated labels including 'Last Update Submitted that Met QC Criteria' capitalization and changed the No FEAR Act data phrasing, with the revision updated to v3.4.0.SummaryDifference0.1%

Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.